ThromboVision Fills Key Positions on Management Team
HOUSTON, January 31, 2007 ----- ThromboVision, Inc., a Houston-based biomedical diagnostics company, has appointed Alan Jernigan to be vice president–worldwide sales & marketing and Richard Thornton to be director of engineering & operations.
Jernigan will spearhead the commercialization of the company’s ThromboGuide (T-Guide®) risk assessment / risk modification platelet function solutions.
Thornton will oversee the final engineering for the T-Guide® and manage day-to-day manufacturing operations.
“As we prepare for clinical trials, Alan and Rick fill critical positions. Their expertise will help ThromboVision move efficiently through the manufacturing and assessment process, as we take the next steps toward commercialization,” said Dr. Edward R. Teitel, president and CEO.
Biographical sketches follow.
Jernigan has also acted as a consultant for the medical device industry, handling sales and marketing as well as setting up distribution networks for European and North American companies.
Jernigan has more than 20 years of domestic and international experience in the healthcare industry in the areas of sales, marketing and business development, including over 10 years of sales management experience.
He received an MBA from Oklahoma City University and a Bachelor of Science from Oklahoma State University.
About Richard Thornton
During more than 25 years of healthcare-related engineering work, he directed multi-million dollar projects from research stage through animal and human clinical trials to market release. His work included software validation and risk analysis documentation to support FDA 510K submission.
Previously, he managed engineering teams for two successful start-up life medical device companies.
Thornton earned a Bachelor of Electrical Engineering from the Georgia Institute of Technology and completed graduate work there in digital signal processing and advanced computer architecture.
ThromboVision, Inc. is a biomedical company committed to enabling people to lead longer and healthier lives. ThromboVision provides easy-to-use, rapid-response, cost-effective, and versatile point-of-care clinical diagnostic discoveries that advance medical diagnosis. The company’s products will improve medical care by assisting physicians in diagnosing and managing critical cardiovascular risk factors. www.thrombovision.com
ThromboVision is a Houston Technology Center (HTC) client company. HTC is a business accelerator that assists Houston-based emerging technology companies in key sectors such as Energy, Information Technology, Life Sciences, Nanotechnology and NASA-originated technologies. www.houstontech.org
SAFE HARBOR STATEMENT
This release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Statements in this release regarding ThromboVision’s business that are not historical facts are “forward-looking statements,” which involve risks and uncertainties that could cause actual results to differ materially from any future results, performance, or achievements expressed or implied by such statements.